Shield Therapeutics (LSE:STX) Interest Expense : £-0.91 Mil (TTM As of Jun. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Shield Therapeutics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Shield Therapeutics's interest expense for the six months ended in Jun. 2023 was £ -0.58 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2023 was £-0.91 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Shield Therapeutics's Operating Income for the six months ended in Jun. 2023 was £ -11.54 Mil. Shield Therapeutics's Interest Expense for the six months ended in Jun. 2023 was £ -0.58 Mil. Shield Therapeutics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Shield Therapeutics Interest Expense Historical Data

The historical data trend for Shield Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shield Therapeutics Interest Expense Chart

Shield Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Interest Expense

Get a 7-Day Free Trial

-0.03

-0.01

-0.33

Shield Therapeutics Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Interest Expense	Get a 7-Day Free Trial													-	-	-	-0.33	-0.58

Shield Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-0.91 Mil.

Shield Therapeutics (LSE:STX) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Shield Therapeutics's Interest Expense for the six months ended in Jun. 2023 was £-0.58 Mil. Its Operating Income for the six months ended in Jun. 2023 was £-11.54 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Jun. 2023 was £5.71 Mil.

Shield Therapeutics's Interest Coverage for the quarter that ended in Jun. 2023 is calculated as

Shield Therapeutics did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Shield Therapeutics (LSE:STX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shield Therapeutics PLC (LSE:STX) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

SHIEF:USA 1JS:Germany

Address

Northern Design Centre, Baltic Business Quarter, Gateshead Quays, Newcastle, GBR, NE8 3DF

Website

https://www.shieldtherapeutics.com

Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals which address areas of high unmet medical need. The company's operating segments are based on key products including Accrufer/Feraccru, used as a novel oral treatment for iron deficiency anemia in patients, which is commercially available, and PT20 used in treating hyperphosphatemia, which is in its last stage of completion. The company generates maximum revenue from Feraccru segment.